Ebola Virus Vaccine Market - By Strain Type (Vesicular Stomatitis Virus (rVSV), Adeno Virus Serotype - 26), End-use (Hospitals, Clinics, Ambulatory Surgical Centers) & Forecast 2023 - 2032

Ebola Virus Vaccine Market Size

Ebola Virus Vaccine Market size accounted for USD 4.4 million in 2022 and is estimated to grow at 32.6% to reach USD 71 million by 2032. The growing incidence of zoonotic diseases across the globe will drive the market expansion.
 

For instance, in 2020, according to the World Health Organization (WHO), around 60% of known infectious diseases and over 75% of emerging infectious diseases are zoonotic in origin. Thus, increasing incidence of zoonotic disease such as Ebola and zoonotic influenza among others is expected to boost the market progression. Furthermore, increasing public health initiatives to prevent and control Ebola outbreaks have resulted in increased investments in vaccine development and procurement, thereby fostering the market trends.
 

Ebola virus vaccines are developed using various approaches, such as viral vectors, recombinant proteins and DNA-based platforms. These vaccines typically contain components of the Ebola virus such as viral proteins or genetic material that are modified or attenuated to be safe for use in humans. When administered, the vaccine triggers an immune response that produces specific antibodies and cellular immunity, providing protection against the Ebola virus.
 

COVID-19 Impact

The COVID-19 pandemic had a significant impact on the Ebola virus vaccine market. Increasing number of COVID-19 cases lead to a shift in focus from developing Ebola vaccines to COVID-19 vaccines. The COVID-19 pandemic and emergence of new variants of the SARS-CoV-2 virus have created the urge of developing COVID-19 vaccine to limit and curb the spread of COVID-19 infection. Thus, owing to such aforementioned factor, a temporary shift shit from addressing Ebola vaccine development was observed, thereby potentially impacted the progress and effectiveness of Ebola vaccine development programs during the period.
 

Ebola Virus Vaccine Market Trends

Increasing research and development efforts for Ebola virus vaccine development is expected to significantly driver the market growth. Various pharmaceutical companies, research institutions and organizations are investing in R&D activities to advance the development of effective vaccines against infectious diseases including Ebola. For instance, in 2021, Bavarian Nordic and Johnson & Johnson partnered to support efforts by the World Health Organization (WHO) to prevent further spread of Ebola in West Africa through the donation of up to 200,000 courses of the Johnson & Johnson Ebola vaccine regimen. Thus, the growing demand to prevent the spread of Ebola in West African countries is expected to drive the market growth.
 

Ebola Virus Vaccine Market Restraint

Stringent regulatory approval of Ebola virus vaccines can significantly hinder the market growth. The complex and rigorous regulatory requirements leads to delay the introduction of new vaccines and limit the entry of new players into the market. Also, increase in approval time and costs associated with vaccine development and commercialization will further hinder the market growth. Furthermore, compliance with stringent regulations necessitates extensive clinical trials, safety evaluations, and manufacturing standards can pose challenges for small scale companies with limited resources. These regulatory hurdles can slow down innovation, limit competition and ultimately restrict the commercialization and availability of Ebola virus vaccines, thereby hampering the market growth.
 

Ebola Virus Vaccine Market Analysis

By strain type, the Ebola virus vaccine market is classified into vesicular stomatitis virus (rVSV) and adeno virus stereotype - 26. The vesicular stomatitis virus (rVSV) segment accounted for 53.9% of the market share in 2022 and is projected to witness robust growth over the analysis timeframe. Ebola virus vaccines utilizing the vesicular stomatitis virus (rVSV) strain have shown promising results in the Ebola vaccine market. The rVSV strain serves as a vector to deliver specific Ebola virus antigens, triggering an immune response in vaccinated individuals. This approach offers several advantages including rapid production capabilities, scalability and the potential for single-dose administration. Moreover, the established safety profile of the rVSV strain makes its more suitable for developing other Ebola virus vaccines. Thus, the aforementioned factors significantly contributed to the market growth.
 

The end-use in Ebola virus vaccine market is categorized into hospitals, clinics, ambulatory surgical centers and other end-users. Hospitals segment accounted for USD 1.6 million market revenue in 2022. Availability of skilled medical professionals and advanced healthcare infrastructure has propelled the hospitals & clinics segment growth. Also, hospitals offer accessibility and convenience for individuals seeking vaccination during their regular visits for healthcare needs. Furthermore, developed infrastructure and well-established storage facilities contributes to streamlined operations and reduces the risk of vaccine shortage as well as wastage in the hospital & clinics. Thus, the aforementioned factors is expected to drive the market growth.
 

U.S. Ebola virus vaccine market accounted for over 52.3% market share in 2022 and is anticipated to grow at considerable growth rate during the forecast timeframe. The increasing prevalence of zoonotic diseases and rising adoption of advanced medical technologies is expected to boost the regional market growth. Also, presence of well-established healthcare infrastructure, key market players and research activities contribute to the growth of Ebola vaccine research & development. Further, growing demand for preventive healthcare, rising government investments to create awareness regarding vaccination and controlling outbreaks will further supplement the expansion of Ebola vaccine market growth in the North America region.
 

Ebola Virus Vaccine Market Share

Major market players operating in the Ebola virus vaccine industry include

• Merck & Co., Inc
• Johnson & Johnson
• Bavarian Nordic
• GlaxoSmithKline plc

These industry players majorly adopt various strategies including collaborations, acquisitions, mergers, and partnerships to create a global footprint and sustain market competition. Also, kindly note that the company profile section include both companies that have commercial drug available in market as well as those that are into clinical phase development.
 

Ebola Virus Vaccine Industry News:

• In July 2020, Johnson & Johnson received European Commission approval for Ebola vaccine regimen for the prevention of Ebola Virus Disease. This strategy approval enables the company to collaborate with World Health Organization (WHO) on vaccine pre-qualification that helped in accelerating registration of its preventive Ebola vaccine regimen in African countries, thereby consolidating its market position.
   
• In December 2019, Merck & Co., Inc. received FDA approval for ERVEBO (Ebola Zaire Vaccine, Live) for the prevention of disease caused by Zaire ebolavirus in individuals 18 years of age and older. This product approval helped the company to enhance its product offerings and consolidate its market presence in Ebola vaccine industry.
   

The Ebola virus vaccine market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032, for the following segments:

Click here to Buy Section of this Report

By Strain Type

• Vesicular Stomatitis Virus (rVSV)
• Adeno Virus Serotype - 26

End-use

• Hospitals
• Clinics
• Ambulatory Surgical Centers
• Other end-users

The above information is provided for the following regions and countries:

• North America
  • U.S.
• Europe
  • Germany
  • France
  • Spain
  • Italy
  • Rest of Europe
• Africa
  • The Democratic Republic of the Congo (DRC)
  • Burundi
  • Ghana
  • Zambia